The revenue for the cell therapy Carvykti and the EGFR-targeted lung cancer duo Rybrevant-Lazcluze contributed to double digit gains in oncology drug sales.

More than just health care for the wealthy, this Bay Area clinic is part of a lucrative and growing industry that sells something priceless: the hope of a longer life.